|
1
|
Vay C, Hosch SB, Stoecklein NH, Klein CA,
Vallböhmer D, Link BC, Yekebas EF, Izbicki JR, Knoefel WT and
Scheunemann P: Integrin expression in esophageal squamous cell
carcinoma: Loss of the physiological integrin expression pattern
correlates with disease progression. PLoS One. 9:e1090262014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen T, Wang C, Wu F, Zhang X, Yang H,
Deng X, He Q, Li W and Li G: Altered localization of p120 catenin
in the cytoplasm rather than the membrane correlates with poor
prognosis in esophageal squamous cell carcinoma. PLoS One.
10:e01186452015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu Y, Wang J, Qiu M and Xu L, Li M, Jiang
F, Yin R and Xu L: Upregulation of the long noncoding RNA TUG1
promotes proliferation and migration of esophageal squamous cell
carcinoma. Tumour Biol. 36:1643–1651. 2015. View Article : Google Scholar
|
|
8
|
McIntire JJ, Umetsu SE, Akbari O, Potter
M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT and DeKruyff RH:
Identification of Tapr (an airway hyperreactivity regulatory locus)
and the linked Tim gene family. Nat Immunol. 2:1109–1116. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Monney L, Sabatos CA, Gaglia JL, Ryu A,
Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel
RA, et al: Th1-specific cell surface protein Tim-3 regulates
macrophage activation and severity of an autoimmune disease.
Nature. 415:536–541. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X,
Liu J, Shi L, Liu C, Wang G, et al: Tim-3/galectin-9 signaling
pathway mediates T-cell dysfunction and predicts poor prognosis in
patients with hepatitis B virus-associated hepatocellular
carcinoma. Hepatology. 56:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fourcade J, Sun Z, Benallaoua M, Guillaume
P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V and Zarour HM:
Upregulation of Tim-3 and PD-1 expression is associated with tumor
antigen-specific CD8+ T cell dysfunction in melanoma
patients. J Exp Med. 207:2175–2186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang
F, Sun J, Yang Q, Zhang X and Lu B: TIM-3 expression characterizes
regulatory T cells in tumor tissues and is associated with lung
cancer progression. PLoS One. 7:e306762012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Piao YR, Jin ZH, Yuan KC and Jin XS:
Analysis of Tim-3 as a therapeutic target in prostate cancer.
Tumour Biol. 35:11409–11414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng G, Li M, Wu J, Ji M, Fang C, Shi H,
Zhu D, Chen L, Zhao J, Shi L, et al: Expression of Tim-3 in gastric
cancer tissue and its relationship with prognosis. Int J Clin Exp
Pathol. 8:9452–9457. 2015.PubMed/NCBI
|
|
16
|
Yang M, Yu Q, Liu J, Fu W, Cao Y, Yu L,
Shao S, Wang X, Niu H and Wang Y: T-cell immunoglobulin mucin-3
expression in bladder urothelial carcinoma: Clinicopathologic
correlations and association with survival. J Surg Oncol.
112:430–435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ling XL, Zhang T, Hou XM and Zhao D:
Clinicopathological significance of fascin-1 expression in patients
with non-small cell lung cancer. Onco Targets Ther. 8:1589–1595.
2015.PubMed/NCBI
|
|
18
|
Li J, Huang H, Sun L, Yang M, Pan C, Chen
W, Wu D, Lin Z, Zeng C, Yao Y, et al: MiR-21 indicates poor
prognosis in tongue squamous cell carcinomas as an apoptosis
inhibitor. Clin Cancer Res. 15:3998–4008. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Loos M, Hedderich DM, Ottenhausen M, Giese
NA, Laschinger M, Esposito I, Kleeff J and Friess H: Expression of
the costimulatory molecule B7-H3 is associated with prolonged
survival in human pancreatic cancer. BMC Cancer. 9:4632009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Herszényi L, Hritz I, Lakatos G, Varga MZ
and Tulassay Z: The behavior of matrix metalloproteinases and their
inhibitors in colorectal cancer. Int J Mol Sci. 13:13240–13263.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Jiang T, Mao A and Xu J:
Esophageal cancer stem cells express PLGF to increase cancer
invasion through MMP9 activation. Tumour Biol. 35:12749–12755.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao G, Kang J, Jiao K, Xu G, Yang L, Tang
S, Zhang H, Wang Y, Nie Y, Wu K, et al: High expression of GRP78
promotes invasion and metastases in patients with esophageal
squamous cell carcinoma. Dig Dis Sci. 60:2690–2699. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The role of snail in EMT and tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu W, Yang Z and Lu N: A new role for the
PI3K/Akt signaling pathway in the epithelial-mesenchymal
transition. Cell Adhes Migr. 9:317–324. 2015. View Article : Google Scholar
|
|
26
|
Wen W, Ding J, Sun W, Fu J, Chen Y, Wu K,
Ning B, Han T, Huang L, Chen C, et al: Cyclin G1-mediated
epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt
signaling facilitates liver cancer progression. Hepatology.
55:1787–1798. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu M, Xu Y, Mao X, Gao Y, Shao L and Yan
F: Overexpression of metastasis-associated in colon cancer-1
associated with poor prognosis in patients with esophageal cancer.
Pathol Oncol Res. 19:749–753. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mohamed A, El-Rayes B, Khuri FR and Saba
NF: Targeted therapies in metastatic esophageal cancer: Advances
over the past decade. Crit Rev Oncol Hematol. 91:186–196. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li LY, Jiang H, Xie YM, Liao LD, Cao HH,
Xu XE, Chen B, Zeng FM, Zhang YL, Du ZP, et al: Macrolide analog
F806 suppresses esophageal squamous cell carcinoma (ESCC) by
blocking β1 integrin activation. Oncotarget. 6:15940–15952. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anderson AC: Tim-3: An emerging target in
the cancer immunotherapy landscape. Cancer Immunol Res. 2:393–398.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang
L, Huang M and Zhou J: Tim-3 expression in cervical cancer promotes
tumor metastasis. PLoS One. 8:e538342013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kikushige Y, Shima T, Takayanagi S, Urata
S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki
Y, et al: TIM-3 is a promising target to selectively kill acute
myeloid leukemia stem cells. Cell Stem Cell. 7:708–717. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jan M, Chao MP, Cha AC, Alizadeh AA,
Gentles AJ, Weissman IL and Majeti R: Prospective separation of
normal and leukemic stem cells based on differential expression of
TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl
Acad Sci USA. 108:5009–5014. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wiener Z, Kohalmi B, Pocza P, Jeager J,
Tolgyesi G, Toth S, Gorbe E, Papp Z and Falus A: TIM-3 is expressed
in melanoma cells and is upregulated in TGF-beta stimulated mast
cells. J Invest Dermatol. 127:906–914. 2007. View Article : Google Scholar
|
|
35
|
Zhuang X, Zhang X, Xia X, Zhang C, Liang
X, Gao L, Zhang X and Ma C: Ectopic expression of TIM-3 in lung
cancers: A potential independent prognostic factor for patients
with NSCLC. Am J Clin Pathol. 137:978–985. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan J, Jiang B, Zhao H and Huang Q:
Prognostic implication of TIM-3 in clear cell renal cell carcinoma.
Neoplasma. 61:35–40. 2014. View Article : Google Scholar
|
|
37
|
Komohara Y, Morita T, Annan DA, Horlad H,
Ohnishi K, Yamada S, Nakayama T, Kitada S, Suzu S, Kinoshita I, et
al: The coordinated actions of TIM-3 on cancer and myeloid cells in
the regulation of tumorigenicity and clinical prognosis in clear
cell renal cell carcinomas. Cancer Immunol Res. 3:999–1007. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hadler-Olsen E, Winberg JO and
Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as
diagnostic and prognostic markers and therapeutic targets. Tumour
Biol. 34:2041–2051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang X, Wang Y, Yamamoto G and Tachikawa
T: Expression of matrix metalloproteinases MMP-2, MMP-9 and their
tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of
salivary gland pleomorphic adenomas. Histopathology. 55:250–260.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jinga DC, Blidaru A, Condrea I, Ardeleanu
C, Dragomir C, Szegli G, Stefanescu M and Matache C: MMP-9 and
MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast
cancer: Correlations with prognostic factors. J Cell Mol Med.
10:499–510. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Groblewska M, Siewko M, Mroczko B and
Szmitkowski M: The role of matrix metalloproteinases (MMPs) and
their inhibitors (TIMPs) in the development of esophageal cancer.
Folia Histochem Cytobiol. 50:12–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Davis FM, Stewart TA, Thompson EW and
Monteith GR: Targeting EMT in cancer: Opportunities for
pharmacological intervention. Trends Pharmacol Sci. 35:479–488.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu WL, Wang WY, Yao WQ and Li GD:
Suppressive effects of microRNA-16 on the proliferation, invasion
and metastasis of hepatocellular carcinoma cells. Int J Mol Med.
36:1713–1719. 2015.PubMed/NCBI
|
|
44
|
Shang Y, Li Z, Li H, Xia H and Lin Z:
TIM-3 expression in human osteosarcoma: Correlation with the
expression of epithelial-mesenchymal transition-specific
biomarkers. Oncol Lett. 6:490–494. 2013.PubMed/NCBI
|
|
45
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by GSK-3β-mediated
phosphorylation in control of epithelial-mesenchymal transition.
Nat Cell Biol. 6:931–940. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu A, Shao C, Jin G, Liu R, Hao J, Song
B, Ouyang L and Hu X: miR-208-induced epithelial to mesenchymal
transition of pancreatic cancer cells promotes cell metastasis and
invasion. Cell Biochem Biophys. 69:341–346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu L, Dai Y, Chen J, Zeng T, Li Y, Chen
L, Zhu YH, Li J, Li Y, Ma S, et al: Maelstrom promotes
hepatocellular carcinoma metastasis by inducing
epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail
signaling. Hepatology. 59:531–543. 2014. View Article : Google Scholar
|
|
48
|
Zhang J, Wei J, Lu J, Tong Z, Liao B, Yu
B, Zheng F, Huang X, Chen Z, Fang Y, et al: Overexpression of Rab25
contributes to metastasis of bladder cancer through induction of
epithelial-mesenchymal transition and activation of
Akt/GSK-3β/Snail signaling. Carcinogenesis. 34:2401–2408. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li Q, Wu J, Wei P, Xu Y, Zhuo C, Wang Y,
Li D and Cai S: Overexpression of forkhead Box C2 promotes tumor
metastasis and indicates poor prognosis in colon cancer via
regulating epithelial-mesenchymal transition. Am J Cancer Res.
5:2022–2034. 2015.PubMed/NCBI
|
